Contract 75N93019C00061

Greffex Inc · Department Of Health And Human Services · September 7, 2021

Cost Plus Fixed FeeFull & Open CompetitionNAICS 541714

Greffex Inc was awarded a federal contract by Department Of Health And Human Services (National Institutes Of Health) on September 7, 2021 for $11.25 million (current value) of work in research and development in biotechnology (except nanobiotechnology). Performance is in Seattle, WA. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses cost-plus contract pricing. The most recent modification was on September 3, 2025. If all options are exercised, the contract could reach $19.12 million.

Current value
$11.25M
Potential value
$19.12M
if all options exercised
Modifications
3
Latest September 3, 2025

Contract details

PIID
75N93019C00061
Award type
Definitive Contract
Pricing
Cost Plus Fixed Fee
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
Product / service
Health R&D Services; Health Care Services; Applied Research
Place of performance
Seattle, WA
First action
September 7, 2021
Latest action
September 3, 2025

Description

THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE 5TH YEAR FUNDS FROM LINE 6

Modification timeline

  • September 3, 2025
    Mod P00028 · Other Administrative Action
    $11.25M
  • July 24, 2024
    Mod P00023 · Other Administrative Action
    EXTEND PERFORMANCE TIME OF OPTIONS DUE TO DELAYS IN CHANGING FROM ONE MANUFACTURING CONTRACTOR TO ANOTHER MANUFACTURING CONTRACTOR.
    $10.83M
  • September 29, 2023
    Mod P00021 · Other Administrative Action
    TO DEVELOP A PLUG-AND-PLAY TECHNOLOGY PLATFORM TO EXPEDITE THE PRODUCTION OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES.
    $9.57M
  • September 7, 2021
    Mod P00012 · Other Administrative Action
    TO DEVELOP A PLUG-AND-PLAY TECHNOLOGY PLATFORM TO EXPEDITE THE PRODUCTION OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES.
    $8.29M

Similar contracts

RecipientAgencyDateObligated
Vericel CorporationDepartment Of Health And Human ServicesApril 1, 2026$34.88M
American College Of Medical Toxicology, Inc.Department Of Health And Human ServicesMarch 31, 2026$0
Ceramedix Holding, LlcDepartment Of Health And Human ServicesMarch 31, 2026$4.22M
Glaxosmithkline, LlcDepartment Of Health And Human ServicesMarch 31, 2026$7.79M
Care Access Research LlcDepartment Of Health And Human ServicesMarch 31, 2026$2.55M
Pattern Bioscience, Inc.Department Of Health And Human ServicesMarch 31, 2026$22.50M

Top contractors in NAICS 541714

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Amgen USA Inc1$59.99M
2Vericel Corporation1$34.88M
3Spectral Md, Inc.1$31.67M
4Ppd Development Lp6$31.12M
5L3 Technologies, Inc.1$22.00M
6Technical Resources International, Inc.6$21.80M
7Abbott Laboratories1$21.01M
8Paratek Pharmaceuticals, Inc1$17.47M
9Ossium Health, Inc.1$12.39M
10Rho Federal Systems Division Inc1$8.00M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 75N93019C00061?

Contract 75N93019C00061 is a federal contract awarded to Greffex Inc by Department Of Health And Human Services on September 7, 2021 for $11.25 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 3 times since the base award.

Who won contract 75N93019C00061?

Greffex Inc won contract 75N93019C00061 from Department Of Health And Human Services.

How much is contract 75N93019C00061 worth?

Contract 75N93019C00061 has obligated $0 to date but carries a potential ceiling of $19.12 million if fully funded and all options are exercised.